Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

NCT01259102 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Buprenorphine transdermal patch

Sponsor

Purdue Pharma LP